1-三苯甲基-4-甲基咪唑 | 82594-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-三苯甲基-4-甲基咪唑
• 英文名称: 4-methyl-1-trityl-1H-imidazole
• 英文别名: 4-Methyl-1-(triphenylmethyl)-1H-imidazole；3-(triphenylmethyl)-5-methylimidazole；1-trityl-4-methylimidazole；4-methyl-1-tritylimidazole
• CAS: 82594-80-7
• 化学式: C₂₃H₂₀N₂
• 分子量: 324.425
• InChiKey: GDROHFZOCLUMKN-UHFFFAOYSA-N

物化性质

• 密度：
  1.05

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Methyl-1-trityl-1H-imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Methyl-1-trityl-1H-imidazole
CAS number: 82594-80-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C23H20N2
Molecular weight: 324.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-三苯甲基-4-甲基咪唑 在 哌啶 、 正丁基锂 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  [EN] LRRK2 INHIBITORS
  [FR] INHIBITEURS DE LRRK2

  摘要：

  公开号：

  WO2012178015A3
• 作为产物：
  描述：

  4-甲基咪唑 、 三苯基氯甲烷 以 三乙胺 、 乙腈 为溶剂， 生成 1-三苯甲基-4-甲基咪唑
  参考文献：
  名称：

  某些新型N取代的唑和吡啶对大鼠肝脏CYP3A活性的影响

  摘要：

  合成了一系列与克霉唑相关的N-取代杂芳族化合物，并确定了这些化合物对大鼠乙硫酰亚胺清除率的影响，以此来衡量它们诱导细胞色素P4503A（CYP3A）活性的能力。乙草胺清除率和体外红霉素N-脱甲基酶活性显示出相关性。在该系列中，咪唑或其他相关的杂芳族“头基”与三苯基甲烷或其他苯基甲烷衍生物连接。在该系列中，发现1-三苯基甲烷取代的咪唑引起CYP3A活性的最大增加，而在三苯基甲基取代的咪唑中，通过间位或Cl-中的F-或Cl-取代获得最高的活性。苯环之一的对位。二苯甲基取代的吡啶实际上没有活性。引起CYP3A活性最大增加的化合物（即1-[（（3-氟苯基）二苯基甲基]咪唑，1-[（（4-氟苯基）二苯基甲基]咪唑和1- [三-（4-氟苯基）甲基]咪唑）产生的乙氧基间苯二酚O-脱烷基酶（EROD）活性（即CYP1A）几乎没有增加，而苄基咪唑仅引起CYP3A活性少量增加，而CYP1A活性几乎增加了9倍。

  DOI：

  10.1016/s0006-2952(98)00096-3

文献信息

• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Buchholz Mirko

  公开号：US20080267911A1

  公开（公告）日：2008-10-30

  Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R 1 represents and R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 , X 4 , Y and Z are as defined throughout the description and the claims.

  式(I)的化合物，其组合物及用途用于疾病治疗，或其药学上可接受的盐、溶剂化合物或多晶形式，包括其所有互变异构体和立体异构体，其中： R1代表，而R2、R3、R4、R5、R6、X1、X2、X3、X4、Y和Z如描述和权利要求中所定义。
• NHC-Pd(II)-azole complexes catalyzed Suzuki–Miyaura cross-coupling of sterically hindered aryl chlorides with arylboronic acids
  作者：Yingying Zhang、Rong Zhang、Chang Ni、Xue Zhang、Yanji Li、Qingwen Lu、Yuxuan Zhao、Fangwai Han、Yongfei Zeng、Guiyan Liu

  DOI：10.1016/j.tetlet.2019.151541

  日期：2020.3

  hindered biaryls efficiently, a series of NHC-Pd(II)-azole complexes bearing sterically hindered ligands were synthesized and characterized. The steric environment effect as well as the electronic effect of the azole ligands has been assessed. All these complexes were applied in the Suzuki−Miyaura cross-coupling reaction of sterically hindered aryl chlorides with low catalysts loadings (0.1 mol %) under

  为了有效地合成受阻联芳基，合成并表征了一系列带有空间受阻配体的NHC-Pd（II）-唑配合物。已经评估了空间环境效应以及唑配体的电子效应。所有这些络合物均在空气中温和条件下，以低催化剂负载量（0.1摩尔％）用于空间受阻芳基氯的Suzuki-Miyaura交叉偶联反应中，并获得良好至优异的空间受阻联芳基分离产率。
• Quinazoline derivatives
  申请人：——

  公开号：US20040034046A1

  公开（公告）日：2004-02-19

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R 1 , n, R 2 and R 3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；它们的制备方法；含有它们的药物组合物；以及它们在制造用作抗侵袭剂的药物中用于抑制和/或治疗实体肿瘤疾病的用途。
• Naphtho(2,1-b) furan derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US04916148A1

  公开（公告）日：1990-04-10

  Naphtho[2,1-b]furan derivatives of the formula: ##STR1## wherein R.sup.1 is a 1H-1,2,4-triazol-1-yl, 4H-1,2,4-triazol-4-yl, 3-pyridyl or 5-pyrimidinyl radical or a 1H-imidazol-1-yl radical optionally substituted in the 5-position by a 1-6C alkyl or halogenoalkyl radical; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen or deuterium atom, a cyano radical, a 1-6C alkyl or halogenoalkyl radical, a phenyl radical optionally substituted by halogen, or one of R.sup.2 and R.sup.3 is a radical of the formula R.sup.1 as defined above, and the other is hydrogen; R.sup.4 and R.sup.5, which may be the same or different, are each a 1-2C alkyl, deuterioalkyl or halogenoalkyl radical; or R.sup.4 and R.sup.5 together with the carbon atom to which they are attached form a 3-6C cycloalkyl radical; R.sup.6 and R.sup.7, which may be the same or different, are each a hydrogen or halogen atom, an amino, carboxy, carbamoyl, cyano, 1-cyano-1-methylethyl or nitro radical, a 1-6C alkyl or halogenoalkyl radical, a mono- or di-(1-6C)alkylcarbamoyl radical, a mono- or di-(1-6C)halogenoalkylcarbamoyl radical, a group of the formula --COR.sup.8, --SO.sub.n R.sup.8 or --OR.sup.8, in which n is 0, 1 or 2 and R.sup.8 is a 1-6C alkyl or halogenoalkyl radical, or a benzoyl radical optionally substituted by halogen; one of R.sup.9 and R.sup.10 is hydrogen and the other is a hydroxy or 1-6C alkoxy radical, or R.sup.9 and R.sup.10 together form an oxo radical; and the pharmaceutically acceptable acid addition salts thereof; processes for their manufacture; and pharmaceutical compositions containing them.

  Naphtho[2,1-b]furan衍生物的化学式：##STR1## 其中R.sup.1是1H-1,2,4-三唑-1-基，4H-1,2,4-三唑-4-基，3-吡啶基或5-嘧啶基或者是在5-位由1-6C烷基或卤代烷基取代的1H-咪唑-1-基；R.sup.2和R.sup.3，可以相同也可以不同，分别是氢或氘原子，氰基，1-6C烷基或卤代烷基，或者是上述定义的R.sup.1的基团，另一个是氢；R.sup.4和R.sup.5，可以相同也可以不同，分别是1-2C烷基，氘代烷基或卤代烷基；或者R.sup.4和R.sup.5与它们连接的碳原子一起形成3-6C环烷基；R.sup.6和R.sup.7，可以相同也可以不同，分别是氢或卤素原子，氨基，羧基，氨基甲基氰基，1-6C烷基或卤代烷基，单或双-(1-6C)烷基氨基甲酰基，单或双-(1-6C)卤代烷基氨基甲酰基，具有化学式--COR.sup.8，--SO.sub.n R.sup.8或--OR.sup.8的基团，其中n为0, 1或2，R.sup.8是1-6C烷基或卤代烷基，或者是可选择由卤素取代的苯甲酰基；R.sup.9和R.sup.10中的一个是氢，另一个是羟基或1-6C烷氧基，或者R.sup.9和R.sup.10一起形成一个醇基；以及其药学上可接受的酸盐；它们的制备方法；以及含有它们的药物组合物。